Acadia Pharma (ACAD) Tops Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.47 +4.38%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.44), $0.12 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $47.06 million.
- ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Enact Holdings (ACT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
